Neurocrine Biosciences Inc. has divulged G protein-coupled receptor GPR52 modulators reported to be useful for the treatment of schizophrenia, obsessive-compulsive disorder, attention deficit hyperactivity disorder, bipolar disorder, vascular cognitive impairment, and Alzheimer’s, Parkinson’s and Huntington’s diseases, among other neurological disorders.
Acerand Therapeutics (USA) Ltd. has identified fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.
Mitobridge Inc. has synthesized dynamin-1-like protein (DNM1L; DRP1) inhibitors reported to be useful for the treatment of cancer, acute kidney injury, metabolic diseases and more.
Astellas Pharma Inc. and Kotobuki Pharmaceutical Co. Ltd. have disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration and inflammatory disorders.
In what represents the first PCT filing to be published in the name of Bayreuth, Germany-headquartered Incontalert GmbH, the company’s co-founders seek protection for a wearable device which employs machine learning techniques to non-invasively predict the bladder filling level for incontinence patients.
Kayothera Inc. has described aldehyde dehydrogenase (ALDH) inhibitors reported to be useful for the treatment of cancer, type 2 diabetes, male contraception and metabolic disease.
Tuojie Biotech (Shanghai) Co. Ltd. has divulged cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of autoimmune diseases, cancer, infections and inflammatory disorders.
Kymera Therapeutics Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a DDB1- and CUL4-associated factor 1 (DCAF1) binding moiety covalently linked to a bromodomain-containing protein 4 (BRD4; HUNK1) targeting moiety.
Neuroninn Biosciences Co. Ltd. has disclosed G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of anxiety, depression, Parkinson’s disease and more.
RSS
